Skip to main content
. 2019 Apr 29;45(2):108–115. doi: 10.5125/jkaoms.2019.45.2.108

Table 3. Staging of patients with high-concentration (Group I) and low-concentration (Group II) bisphosphonate use.

Stage Group I (n=23) Group II (n=29) Total (n=52)
0 3 (13.0) 11 (37.9) 14 (26.9)
1 6 (26.1) 13 (44.8) 19 (36.5)
2 10 (43.5) 5 (17.2) 15 (28.8)
3 4 (17.4) 0 (0) 4 (7.7)

χ2=12.23, P<0.01.